Compare

Zevra Therapeutics/$ZVRA

1D1W1M3M6MYTD1Y5YMAX

About Zevra Therapeutics

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Ticker
$ZVRA
Sector
Health
Primary listing
NASDAQ
Employees
61

ZVRA Metrics

BasicAdvanced
$550M
7.52
$1.23
0.99
-

What the Analysts think about ZVRA

Analyst ratings (Buy, Hold, Sell) for Zevra Therapeutics stock.
Analyst projections of the future price of Zevra Therapeutics stock.

Bulls say / Bears say

MIPLYFFA sales reached $34.0 million in Q3, up 52% year on year and 12.6% from the previous quarter, driving total revenue growth of 45%. This gives Zevra a growing commercial base in the US. (Zevra Therapeutics)
Zevra had $270.9 million in cash, cash equivalents and investments at quarter-end and had repaid its term debt. That gives it financial room to fund commercial operations and development without an immediate need to raise capital. (SEC)
A planned Q1 2027 filing could extend MIPLYFFA’s use to infants under two. The small five-patient study found no new safety signals, offering a possible route to treat patients earlier in the disease course. (Zevra Therapeutics, Zevra Therapeutics)
The EMA’s review committee again recommended refusing arimoclomol in Europe, citing a failure to establish sufficient benefit. A final European Commission decision is still pending, but the setback weakens the case for near-term European sales. (Zevra Therapeutics)
The business is heavily dependent on MIPLYFFA, which generated $34.0 million of Q3’s $37.8 million revenue, while just 13 prescription enrollment forms were received that quarter. Continued growth therefore depends on finding and treating more patients in a rare, hard-to-diagnose disease population. (SEC, Zevra Therapeutics)
Expanded-access reimbursements can make reported revenue uneven: they fell to $3.6 million in Q3 from $9.0 million in Q2. Zevra also held a $14.8 million reserve for potential French price clawbacks, which could reduce the value of those receipts. (SEC, Zevra Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 13 Nov 2026.

ZVRA Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

ZVRA Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing ZVRA

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.